|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 309.66 USD | -1.20% |
|
-0.36% | +1.93% |
| 04-10 | BeOne Medicines Says Tarlatamab Received Marketing Authorization in China for Small Cell Lung Cancer Treatment | MT |
| 04-10 | Wall Street Gets a CPI Lifeline |  |
Business description: BeOne Medicines AG
Number of employees: 12,000
Sales by Activity: BeOne Medicines AG
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Pharmaceutical Products | 1.18B | 1.42B | 2.46B | 3.81B | 5.34B |
Geographical breakdown of sales: BeOne Medicines AG
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States (U.S) | 495M | 503M | 1.13B | 1.96B | 2.88B |
China | 517M | 840M | 1.1B | 1.41B | 1.68B |
Europe | - | - | 202M | 363M | 611M |
Rest of World | 164M | 73.26M | 26.6M | 78.81M | 172M |
Executive Committee: BeOne Medicines AG
| Manager | Title | Age | Since |
|---|---|---|---|
John Oyler
CEO | Chief Executive Officer | 57 | 28/10/2010 |
Xiao Bin Wu
PSD | President | 64 | 01/04/2018 |
Aaron Rosenberg
DFI | Director of Finance/CFO | 50 | 22/07/2024 |
Lai Wang
PSD | President | 49 | 17/12/2025 |
Marcello Damiani
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/05/2025 |
Composition of the Board of Directors: BeOne Medicines AG
| Director | Title | Age | Since |
|---|---|---|---|
John Oyler
CHM | Chairman | 57 | 27/01/2016 |
Michael Goller
BRD | Director/Board Member | 51 | 01/04/2015 |
Ranjeev Krishana
BRD | Director/Board Member | 52 | 01/10/2014 |
Qing Qing Yi
BRD | Director/Board Member | 54 | 01/10/2014 |
Xiao Dong Wang
CHM | Chairman | 62 | 28/10/2010 |
Anthony Hooper
BRD | Director/Board Member | 71 | 01/01/2020 |
Corazon Sanders
BRD | Director/Board Member | 69 | 24/08/2020 |
Alessandro Riva
BRD | Director/Board Member | 65 | 01/02/2022 |
Margaret Dugan
BRD | Director/Board Member | 69 | 01/02/2022 |
| Director/Board Member | 70 | 22/01/2024 |
Holdings: BeOne Medicines AG
| Name | Equities | % | Valuation |
|---|---|---|---|
| 1,215,306 | 2.15% | 758 351 $ |
Company details: BeOne Medicines AG
Other Biotechnology & Medical Research
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.20% | -0.36% | +48.65% | +31.77% | 34.34B | |
| +1.74% | +0.55% | -1.27% | -9.27% | 45.62B | |
| -0.89% | +2.25% | +26.48% | +33.05% | 29.46B | |
| -0.97% | -3.42% | +16.84% | -15.01% | 28.09B | |
| +0.22% | -2.71% | +186.40% | +369.47% | 19.11B | |
| -1.01% | +4.38% | +66.94% | +223.70% | 14.78B | |
| +2.31% | -6.43% | +3,777.83% | +3,935.28% | 14.25B | |
| -1.59% | -0.97% | +74.81% | +158.73% | 14.09B | |
| +0.25% | -4.10% | +37.01% | +4.36% | 13.25B | |
| -1.65% | +0.51% | +181.43% | +103.66% | 12.42B | |
| Average | -0.28% | -1.06% | +441.51% | +483.58% | 22.54B | |
| Weighted average by Cap. | -0.14% | -0.73% | +288.60% | +316.10% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ONC Stock
- Company BeOne Medicines AG
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition